What is Sialanar used for?

Sialanar is indicated for Chronic obstructive lung disease, Excessive salivation, General anesthesia, Hyperhidrosis of axilla, Peptic ulcer.

Sialanar is developed by Proveca Pharma Limited.

What development phase is Sialanar in?

Sialanar is FDA-approved (marketed).

Last reviewed 2026-04-19 · How we verify

Sialanar

Proveca Pharma Limited · FDA-approved active Small molecule

At a glance

Generic name	Sialanar
Sponsor	Proveca Pharma Limited
Target	Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
Modality	Small molecule
Therapeutic area	Respiratory
Phase	FDA-approved

Approved indications

Chronic obstructive lung disease
Excessive salivation
General anesthesia
Hyperhidrosis of axilla
Peptic ulcer
Vagal Reflex Bradycardia

Common side effects

No common side effects on file.

Key clinical trials

Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties, (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Sialanar CI brief — competitive landscape report
Sialanar updates RSS · CI watch RSS
Proveca Pharma Limited portfolio CI